Filter
25
Filtered Results: 25
Text search:
nirmatrelvir
Featured
Recommendations
12
Language
Document type
Fact sheets
11
Guidelines
8
Studies & Reports
2
Strategic & Response Plan
2
Manuals
1
No document type
1
Countries / Regions
Latin America and the Carribbean
3
Global
1
Authors & Publishers
Publication Years
Category
COVID-19
2
Infection Control & Prevention (IPC)
1
Guidelines
1
Studies & Reports
1
Statistics
1
Pharmacy & Technologies
1
Toolboxes
Clinical Guidelines
18
COVAX Initiative
2
Situation Reports & Updates
1
Global Impact: Socio-economic, health services, TB & HIV
1
Access & Strategy
1
Fair Allocation & Ethical Aspects
1
SARS-CoV-2 Variants
1
Essential Medicines
1
Prices and Patents
1
Reports & Studies
1
Global Overview
1
Human Rights & the Right to Health
1
Nirmatrelvir-ritonavir for COVID-19
recommended
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
Molnupiravir for COVID-19
recommended
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
Remdesivir for COVID-19
recommended
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
Administration of Remdesivir for COVID-19
recommended
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for...
The World Health Organization (WHO) recognizes the challenges countries face for maintaining their COVID-19 response while addressing competing public health challenges, conflicts, climate change and economic crises. WHO continues to support countries in adjusting COVID-19 strategies to reflect succ...
This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi...
26 de abril del 2022. La Organización Panamericana de la Salud presenta estas consideraciones con el fin de apoyar la toma de decisiones relativa al manejo de pacientes con COVID-19 en la Región de las Américas. Las recomendaciones tienen en cuenta la evidencia más reciente, el estado de vacunac...
Globally each year, millions of people suffer illness or lose their lives because the vaccines, medicines and diagnostic tests that they need are either unavailable or unaffordable – and this lack of access to medicine is acute in low- and middle-in-
come countries (LMICs). While the COVID-19 pan...
The WHO Pharmaceuticals Newsletter provides you with the latest information on the safety of medicinal products and regulatory actions taken by authorities around the world.
In addition, this edition includes summary and recommendations from the virtual meeting of the members of the WHO Programme f...
Reseña normativa de la OMS:
31 Oct 2022 his plan outlines how the ACT-Accelerator will support countries as the world transitions to long-term COVID-19 control.
Recognizing the evolving nature of the COVID-19 virus and pandemic, the plan outlines changes to ACT-A’s set-up and ways of working, to ensure countries co...
This report’s central premise is that diagnostics and therapeutics, and associated test to treat strategies, are fundamental components of the pandemic response, both for COVID-19 and for future health threats. Two years into the COVID-19 pandemic, this report reflects on the main challenges and k...
